Harmony Biosciences Reports Strong 2025 Revenue, Reiterates 2026 Guidance, Despite Q4 Profit Decline

summarizeSummary

Harmony Biosciences announced strong full-year 2025 revenue and reiterated its 2026 WAKIX revenue guidance of over $1 billion, but reported a significant decline in Q4 2025 net income due to increased operating expenses.

check_boxKey Events

• Strong 2025 Revenue Growth

  Full-year 2025 net product revenue for WAKIX reached $868.5 million, a 22% increase year-over-year, with Q4 2025 revenue growing 21% to $243.8 million.

• Reiterated 2026 Revenue Guidance

  The company reiterated its 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion, signaling confidence in achieving blockbuster status.

• Significant Q4 Profit Decline

  Despite revenue growth, Q4 2025 GAAP net income decreased 55% to $22.5 million, and Non-GAAP adjusted net income fell 48% to $33.4 million, primarily due to a 50% increase in total operating expenses.

• WAKIX Franchise Protection & Expansion

  Completed settlements with 3 additional generic filers, extending WAKIX franchise protection until at least March 2030, and received FDA approval for pediatric cataplexy.

auto_awesomeAnalysis

This 8-K details Harmony Biosciences' Q4 and full-year 2025 financial results, confirming robust revenue growth for WAKIX, which is on track to achieve blockbuster status in 2026. The company reiterated its strong 2026 revenue guidance of $1.0 billion to $1.04 billion, previously announced on January 12, 2026. However, the filing also revealed a substantial decrease in Q4 2025 GAAP and Non-GAAP net income, primarily driven by a significant increase in R&D and G&A expenses. While increased R&D reflects investment in a robust late-stage pipeline, the near doubling of G&A expenses warrants attention. Positive long-term developments include FDA approval for pediatric cataplexy, settlements with generic filers extending WAKIX franchise protection into the 2030s, and progress on new pitolisant formulations and other pipeline assets aimed at expanding into broader CNS indications and extending patent life into the 2040s. Investors should weigh the strong top-line growth and pipeline advancements against the recent pressure on quarterly profitability.